Partial
Partially Aligned
Patient Risk:
Low
Summary
The core claim that ezetimibe may be taken with or without food is supported by the label excerpt, but several additional food/timing absorption/efficacy and statin-coadministration consistency claims are not supported or are only partially supported by the provided prescribing information.
Category Scores
Accurate Statements
Ezetimibe can generally be taken with or without food.
2 DOSAGE AND ADMINISTRATION: “The recommended dose of ZETIA is 10 mg orally once daily, administered with or without food.”
Food does not create a requirement that ezetimibe must be taken with meals.
2 DOSAGE AND ADMINISTRATION: “...administered with or without food.”
Unsupported Statements
Taking ezetimibe without food does not typically require a timing adjustment.
Not explicitly stated in the provided label excerpt.
Ezetimibe and a statin can usually be taken together with or without food.
Not supported by the provided label sections/excerpt.
The key requirement for ezetimibe (when used with a statin) is taking the medicine consistently as prescribed.
Not supported by the provided label sections/excerpt.
Food may change how quickly an ezetimibe dose is absorbed.
Not supported by the provided label sections/excerpt.
Contradictions
Important Omissions
No label support assessed for missed-dose instructions, bile-acid sequestrant spacing, or clinical LDL-C assessment timing (present in the excerpt).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The only clearly supported claims relate to administration with or without food. However, several additional claims about absorption timing/efficacy/statin use were not supported by the provided label excerpt; these omissions primarily affect labeling accuracy rather than directly contradicting safety-critical instructions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple food/timing and statin-coadministration claims are absent from or not evidenced by the provided prescribing information excerpt.
Suggested Improvement
Limit claims to what is explicitly supported (e.g., “administered with or without food”) unless additional label text is provided to support statements about efficacy without food, absorption speed changes, and combined use with statins.